Cell Therapy Market (By Therapy Type: Autologous, Allogeneic; By Therapeutic Area) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global cell therapy market size was estimated at around USD 4.77 billion in 2023 and it is projected to hit around USD 36.83 billion by 2033, growing at a CAGR of 22.68% from 2024 to 2033. The cell therapy market is driven by rising prevalence of chronic diseases, advancements in gene editing technologies, personalized medicine, allogeneic cell therapies for scalability, and integration of artificial intelligence (ai).

Cell Therapy Market Size 2024 to 2033

Key Pointers

  • North America dominated the market with the largest market share of 59% in 2023.
  • Asia Pacific is anticipated to grow at the noteworthy CAGR from 2024 to 2033.
  • By Therapy Type, the autologous therapy segment held the largest revenue share of 92% in 2023.
  • By Therapy Type, the allogeneic cell therapy segment is expected to experience substantial growth in the market from 2024 to 2033.
  • By Therapeutic Area, the oncology contributed the largest market share in 2023.

Cell Therapy Market Overview

The field of cell therapy has witnessed remarkable growth and innovation in recent years, positioning itself at the forefront of medical advancements. This article provides a comprehensive overview of the current state of the cell therapy market, highlighting key trends, challenges, and opportunities that shape its dynamic landscape.

Cell Therapy Market Growth

The cell therapy market is experiencing robust growth, propelled by several key factors. One significant driver is the increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, prompting a heightened demand for innovative treatment modalities. The shift towards personalized medicine, facilitated by advancements in genomics and molecular biology, has also fueled market expansion. Furthermore, the continuous evolution of gene editing technologies, such as CRISPR-Cas9, enhances the precision and efficacy of cell therapies, contributing to their growing acceptance. Collaborations between pharmaceutical companies, biotechnology firms, and academic institutions further stimulate research and development activities, fostering innovation in the field. The rising interest in allogeneic cell therapies, offering scalable and off-the-shelf solutions, adds another dimension to the market's growth. As regulatory frameworks become more defined and streamlined, providing a clearer pathway for product approvals, the cell therapy market is poised for sustained expansion in the coming years.

Cell Therapy Market Trends:

  • Personalized Medicine: The cell therapy market is witnessing a notable trend towards personalized medicine, where therapies are tailored to individual patients based on their unique genetic profiles. This approach enhances treatment precision and efficacy.
  • Advancements in Gene Editing Technologies: Technological breakthroughs, particularly in gene editing tools like CRISPR-Cas9, are significantly influencing the cell therapy landscape. These innovations allow for more accurate modification of cells, improving therapeutic outcomes.
  • Rise of Allogeneic Cell Therapies: There is a growing interest in allogeneic cell therapies, which utilize cells from donors rather than the patient. This approach offers scalability and the potential for off-the-shelf solutions, addressing some of the manufacturing challenges associated with personalized therapies.
  • Expansion into Diverse Therapeutic Areas: The application of cell therapy is expanding into various therapeutic areas beyond oncology, including neurodegenerative diseases, cardiovascular disorders, and autoimmune conditions. This diversification opens up new avenues for market growth.
  • Focus on Regulatory Compliance: With the maturation of the cell therapy field, there is a heightened focus on regulatory compliance. Regulatory bodies, such as the FDA and EMA, play a crucial role in ensuring the safety and efficacy of cell therapies, shaping the industry's development.
  • Growing Public Awareness and Acceptance: As cell therapies gain prominence, there is a parallel increase in public awareness and acceptance. This growing recognition fosters a more favorable environment for the market, both in terms of investment and patient adoption.
  • Integration of Artificial Intelligence (AI): The integration of AI in cell therapy research and development processes is becoming more prevalent. AI applications contribute to data analysis, prediction of treatment outcomes, and optimization of manufacturing processes, enhancing overall efficiency and success rates.
  • Emergence of Next-Generation Platforms: The development of next-generation cell therapy platforms is a trend driving innovation. These platforms aim to address current challenges such as scalability, manufacturing complexities, and delivery mechanisms, paving the way for more accessible and effective therapies.

Therapy Type Insights

In 2023, the autologous therapy segment dominated the market, holding a significant share of 92%. The growth of this segment can be attributed to the widespread adoption of various CAR-T therapies, known for their favorable outcomes in treating diverse cancers and genetic disorders. Several of these therapies have received approval from the FDA, and their increasing adoption is currently in progress. Notably, in February 2022, the U.S. FDA approved ciltacabtagene autoleucel (Carvykti) for adult patients with multiple myeloma unresponsive to refractory therapeutics or experiencing relapse after treatment.

Cell Therapy Market Share, By Therapy Type, 2023 (%)

Looking ahead, the allogeneic cell therapy segment is expected to experience substantial growth in the market from 2024 to 2033. This growth is driven by the high adoption of allogeneic therapies in designing innovative therapeutic regimens. The global pipeline currently boasts 542 active allogenic CAR-T agents, with many showing promising outcomes. For instance, Adaptimmune Ltd. has collaborated with Genentech to explore the utility of allogeneic therapies derived from induced pluripotent stem cells (iPSCs) in creating T-cells with a higher proliferation capacity than mature T-cells

Therapeutic Area Insights

In 2023, the oncology segment emerged as the market leader, boasting the largest share of revenue. CAR T-cells specifically targeting CD19 have demonstrated notable success in achieving high rates of complete and enduring remissions among patients with acute lymphocytic leukemia (ALL). The continuous increase in FDA approvals for innovative therapies is poised to unlock further growth opportunities for the market. Notably, in October 2021, the U.S. FDA granted approval for brexucabtagene autoleucel (Tecartus), a CAR T therapy designed for individuals with B-cell precursor ALL who have not responded to prior treatment (refractory) or have experienced a relapse after treatment. This milestone marked brexucabtagene as the inaugural CAR T treatment approved for adults with ALL.

Looking ahead, the musculoskeletal disorders segment is anticipated to experience substantial market expansion in the coming years. Significant research efforts are underway to develop technologies capable of regenerating or restoring impaired musculoskeletal tissues. Researchers from diverse groups are exploring clinically applicable cell types for therapies addressing musculoskeletal tissue degeneration. Additionally, there is exploration into the direct application of engineered or native skeletal progenitor cells to stimulate tissue repair and rejuvenate musculoskeletal tissues, driving growth within the segment.

Regional Insights

In 2023, North America claimed the largest revenue share, accounting for 59%. This dominance is attributed to collaborative research initiatives between research institutes and pharmaceutical giants, fostering emerging advancements through numerous partnerships. A noteworthy collaboration occurred in June 2022 when Immatics partnered with Bristol Myers Squibb to develop Gamma Delta Allogeneic Cell Therapy Programs. The availability of substantial funds from government organizations significantly contributes to market growth in the U.S. An example is Cellino Biotech, which, in January 2022, raised approximately USD 80 million through a Series A financing round from investors like 8VC and Felicis Ventures. 

Cell Therapy Market Share, By Region, 2023 (%)

Asia Pacific is anticipated to register a substantial Compound Annual Growth Rate (CAGR) during the forecast period, driven by the increasing demand for cell therapy in the region. Factors such as growing awareness about novel therapies, increased investments, and anticipated favorable government policies are expected to accelerate market growth. For instance, in June 2022, Tessa Therapeutics Ltd. secured USD 126 million through series funding rounds to propel the development of next-generation cancer therapy. Likewise, the South Korean market is projected to exhibit lucrative growth due to strategic initiatives by local and international companies. A case in point is Panacell Biotech, which announced in August 2022 its plans to utilize Natural Killer (NK) cells, brown Adipose-Derived Stem Cells (ADSC), and exosomes for treating COVID-19 infection.

Recent Developments

  • In October 2023, Nkarta, Inc. announced the FDA's approval of an IND application to investigate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, to cure lupus nephritis.

  • In June 2023, Vertex Pharmaceuticals Incorporated and Lonza revealed a joint venture to facilitate the manufacturing of Vertex's portfolios of investigational stem cell therapies. These therapies are designed to aid individuals with Type 1 Diabetes (T1D), with a specific focus on the VX-880 and VX-264 programs currently undergoing clinical trials.

  • In May 2023, Johnson & Johnson signed a global collaboration & licensing agreement with Cellular Biomedicine Group to develop next-generation CAR-T therapies.

Cell Therapy Market Key Companies

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • JW Therapeutics
  • Atara Biotherapeutics
  • Anterogen Co., Ltd.
  • MEDIPOST
  • S. BIOMEDICS
  • Aurion Biotech
  • Holostem Terapie Avanzate S.r.l
  • Nkarta, Inc.

Cell Therapy Market Segmentations:

By Therapy Type

  • Allogeneic Therapies
    • Stem Cell Therapies
      • Hematopoietic Stem Cell Therapies
      • Mesenchymal Stem Cell Therapies
    • Non-Stem Cell Therapies
      • Keratinocytes & Fibroblast-based Therapies
      • Others
  • Autologous Therapies
    • Stem Cell Therapies
      • BM, Blood, & Umbilical Cord-derived Stem Cells
      • Adipose Derived Cells
      • Others
    • Non-Stem Cell Therapies
      • T-Cell Therapies
        • CAR T Cell Therapy
        • T Cell Receptor (TCR)-based
    • Others

By Therapeutic Area

  • Oncology
  • Cardiovascular Disease (CVD)
  • Musculoskeletal Disorders
  • Dermatology
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Frequently Asked Questions

The global cell therapy market size was reached at USD 4.77 billion in 2023 and it is projected to hit around USD 36.83 billion by 2033.

The global cell therapy market is growing at a compound annual growth rate (CAGR) of 22.68% from 2024 to 2033.

The North America region has accounted for the largest cell therapy market share in 2023.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell Therapy Market 

5.1. COVID-19 Landscape: Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell Therapy Market, By Therapy Type

8.1. Cell Therapy Market, by Therapy Type, 2024-2033

8.1.1. Allogeneic Therapies

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Autologous Therapies

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Cell Therapy Market, By Therapeutic Area

9.1. Cell Therapy Market, by Therapeutic Area, 2024-2033

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Cardiovascular Disease (CVD)

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Musculoskeletal Disorders

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Dermatology

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Cell Therapy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.1.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.2.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2033)

Chapter 11. Company Profiles

11.1. Novartis AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Gilead Sciences, Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Bristol-Myers Squibb Company

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Johnson & Johnson Services, Inc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. JCR Pharmaceuticals Co., Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. JW Therapeutics

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Atara Biotherapeutics

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Anterogen Co., Ltd.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. MEDIPOST

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. S. BIOMEDICS

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers